Occasion: 2024 Maxim Healthcare Digital Summit
Date:
Time:
Webcast hyperlink: 2024 Maxim Healthcare Digital Summit
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical firm targeted on the event and commercialization of modern therapies to be used in medically supervised settings. Talphera’s lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is presently being studied underneath an investigational gadget exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has obtained Breakthrough Gadget Designation standing from the U.S. Meals and Drug Administration (FDA).
This launch is meant for buyers solely. For added details about Talphera, please go to www.talphera.com.